mesalamine rectal suppository
Selected indexed studies
- [Ulcerative colitis]. (Praxis (Bern 1994), 2016) [PMID:27223413]
- Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. (Clin Exp Gastroenterol, 2016) [PMID:27274301]
- Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. (Inflamm Bowel Dis, 2015) [PMID:26313693]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial. (2022) pubmed
- [Ulcerative colitis]. (2016) pubmed
- Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. (2016) pubmed
- Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. (2016) pubmed
- pH and redox dual response nano-suppository for the treatment of ulcerative colitis. (2024) pubmed
- Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. (2010) pubmed
- [Mesalazine-induced acute hepatitis]. (2015) pubmed
- Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. (2015) pubmed
- Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU. (2025) pubmed
- Topical treatment of ulcerative colitis. (1990) pubmed